Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE)

Sector: Healthcare Industry: Biotechnology CIK: 0001826457
P/B 4.34
P/E 50.97
P/S 5.88
Market Cap 1.07 Bn
ROIC (Qtr) 2.56
Div Yield % 0.00
Rev 1y % (Qtr) 38.54
Total Debt (Qtr) 40.17 Mn
Debt/Equity (Qtr) 0.16

About

Stock Price Chart

Analysis

Pros

  • Strong operating cash flow of 149.14M provides robust 3.71x coverage of total debt 40.17M, indicating excellent debt servicing capability and financial flexibility.
  • Healthy cash reserves of 213.29M provide 50.29x coverage of short-term debt 4.24M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 459.84M provides 11.45x coverage of total debt 40.17M, indicating robust asset backing and low credit risk.
  • Strong operating cash flow of 149.14M provides 4.31x coverage of SG&A expenses 34.64M, showing efficient operational cost management.
  • Robust free cash flow of 145.02M exceeds capital expenditure of 4.12M by 35.23x, indicating strong organic growth funding capability.

Cons

  • Operating cash flow of 149.14M barely covers its investment activities of (67.66M), with a coverage ratio of -2.20, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (67.66M) provide weak support for R&D spending of 138.39M, which is -0.49x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of 149.14M provides insufficient coverage of deferred revenue obligations of 136.69M, which is 1.09x, raising concerns about future service delivery capabilities.
  • Operating earnings of 21.95M show weak coverage of depreciation charges of 8.33M, with a 2.64 ratio indicating high capital intensity and potential reinvestment needs.
  • Tangible assets of 459.84M provide limited backing for working capital of 340.37M, which is 1.35x, suggesting increased operational risk in market downturns.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 2.25 12.31
EV to Cash from Ops. 6.94 23.25
EV to Debt 25.75 738.44
EV to EBIT 47.11 -9.16
EV to EBITDA 61.42 6.95
EV to Free Cash Flow [EV/FCF] 7.13 21.90
EV to Market Cap 0.97 65.67
EV to Revenue 5.70 227.32
Price to Book Value [P/B] 4.34 22.34
Price to Earnings [P/E] 50.97 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 25.08 -27.13
Cash and Equivalents Growth (1y) % 63.46 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 117.54 -46.93
EBITDA Growth (1y) % 113.91 -1.68
EBIT Growth (1y) % 118.45 -56.45
EBT Growth (1y) % 118.45 -12.70
EPS Growth (1y) % 117.58 -28.31
FCF Growth (1y) % 330.98 -31.90
Gross Profit Growth (1y) % 1,112.27 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.39 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 3.47 3.85
Current Ratio 6.54 7.27
Debt to Equity Ratio 0.16 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 16.70 -18,234.31
EBIT Margin % 12.09 -18,580.80
EBT Margin % 12.09 -19,488.74
Gross Margin % 100.00 -7.59
Net Profit Margin % 11.50 -19,439.22